CA3020792A1 - Conjugates comprising ripk2 inhibitors - Google Patents

Conjugates comprising ripk2 inhibitors Download PDF

Info

Publication number
CA3020792A1
CA3020792A1 CA3020792A CA3020792A CA3020792A1 CA 3020792 A1 CA3020792 A1 CA 3020792A1 CA 3020792 A CA3020792 A CA 3020792A CA 3020792 A CA3020792 A CA 3020792A CA 3020792 A1 CA3020792 A1 CA 3020792A1
Authority
CA
Canada
Prior art keywords
tert
dimethyl
methylpiperazin
pyrazol
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3020792A
Other languages
English (en)
French (fr)
Inventor
Linda N. Casillas
John David Harling
Afjal Hussain MIAH
Ian Edward David Smith
Mark David RACKHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CA3020792A1 publication Critical patent/CA3020792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3020792A 2016-04-20 2017-04-18 Conjugates comprising ripk2 inhibitors Abandoned CA3020792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324944P 2016-04-20 2016-04-20
US62/324,944 2016-04-20
PCT/EP2017/059090 WO2017182418A1 (en) 2016-04-20 2017-04-18 Conjugates comprising ripk2 inhibitors

Publications (1)

Publication Number Publication Date
CA3020792A1 true CA3020792A1 (en) 2017-10-26

Family

ID=58548715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020792A Abandoned CA3020792A1 (en) 2016-04-20 2017-04-18 Conjugates comprising ripk2 inhibitors

Country Status (10)

Country Link
US (1) US10781205B2 (enExample)
EP (1) EP3445759A1 (enExample)
JP (1) JP2019514878A (enExample)
KR (1) KR20180135038A (enExample)
CN (1) CN109311867A (enExample)
AU (1) AU2017253560B2 (enExample)
BR (1) BR112018071408A2 (enExample)
CA (1) CA3020792A1 (enExample)
RU (1) RU2018134981A (enExample)
WO (1) WO2017182418A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CN112533918A (zh) 2018-06-13 2021-03-19 安菲斯塔治疗有限责任公司 用于靶向Rpn11的双功能分子
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
CN112638905A (zh) * 2018-08-28 2021-04-09 南京明德新药研发有限公司 作为rip2激酶抑制剂的喹唑啉类衍生物
CA3133314A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
JP2021024787A (ja) 2019-07-31 2021-02-22 ファイメクス株式会社 複素環化合物
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
EP4291193A4 (en) 2021-02-10 2025-05-07 BeiGene Switzerland GmbH Egfr degraders and methods of use
CN114014890A (zh) * 2021-03-12 2022-02-08 爱科诺生物医药(香港)有限公司 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用
MX2024008060A (es) 2021-12-30 2024-07-10 Beigene Switzerland Gmbh Degradacion de la tirosina quinasa de bruton (btk) mediante conjugacion de inhibidores de la btk con ligando de ligasa e3 y metodos de uso.
JPWO2024071371A1 (enExample) * 2022-09-30 2024-04-04
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
KR20260020383A (ko) 2023-05-31 2026-02-11 비원 메디슨즈 아이 게엠베하 Egfr 키나제의 분해를 위한 화합물
WO2025092821A1 (zh) * 2023-11-01 2025-05-08 成都赜灵生物医药科技有限公司 喹唑啉衍生物类ripk2抑制剂及其用途
WO2025126115A1 (en) 2023-12-13 2025-06-19 Beigene Switzerland Gmbh Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
HRP20140885T1 (hr) 2007-04-13 2014-11-21 The Regents Of The University Of Michigan Diazo bicikliäśki smac mimetici i njihove primjene
WO2009140447A1 (en) * 2008-05-16 2009-11-19 Novartis Ag Immunomodulation by iap inhibitors
BR112012003118A2 (pt) 2009-08-12 2016-02-23 Novartis Ag formulações orais sólidas e formas cristalinas de um inibidor de proteína apoptose
ES2552977T3 (es) 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
UY33549A (es) 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012122011A2 (en) * 2011-03-04 2012-09-13 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
ES2654623T3 (es) 2012-08-23 2018-02-14 The Regents Of The University Of Michigan Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
US9603889B2 (en) 2012-10-02 2017-03-28 Bristol-Myers Squibb Company IAP antagonists
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9409888B2 (en) 2012-12-11 2016-08-09 Hoffmann-La Roche Inc. Dimeric compounds
KR101335240B1 (ko) 2012-12-13 2013-11-29 전호건 수평 연속 방식의 탄화장치
TWI630203B (zh) 2013-02-21 2018-07-21 葛蘭素史克智慧財產發展有限公司 做為激酶抑制劑的喹唑啉類
GB201311891D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds

Also Published As

Publication number Publication date
KR20180135038A (ko) 2018-12-19
JP2019514878A (ja) 2019-06-06
RU2018134981A (ru) 2020-05-20
EP3445759A1 (en) 2019-02-27
US20190119271A1 (en) 2019-04-25
CN109311867A (zh) 2019-02-05
AU2017253560B2 (en) 2019-03-21
US10781205B2 (en) 2020-09-22
BR112018071408A2 (pt) 2019-02-05
WO2017182418A1 (en) 2017-10-26
AU2017253560A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
AU2017253560B2 (en) Conjugates comprising RIPK2 inhibitors
AU2016252404B2 (en) Novel compounds
CN112778276B (zh) 作为shp2抑制剂的化合物及其应用
CA2926207C (en) Heteroaryl compounds as btk inhibitors and uses thereof
DK3050882T3 (en) PIPERIDIN-4-YL-AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
CA2947338C (en) Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor
RU2677884C2 (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
US8633206B2 (en) Pyrrolo[2,3-D]pyrimidine compounds
CA3070171A1 (en) Tlr7/8 antagonists and uses thereof
JP6166845B2 (ja) ２，６−置換プリン誘導体および増殖性障害の治療におけるそれらの使用
CA3005766A1 (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
CA2978170A1 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
HUE033587T2 (hu) Bipirazol-származékok mint JAK inhibitorok
CN116348469B (zh) 一种高活性Wnt通路抑制剂化合物
CA2846187A1 (en) Pyrimido-pyridazinone compounds and use thereof
EP4562007A1 (en) Targeted protein degradation of parp14 for use in therapy
HK30089210A2 (en) A highly active wnt pathway inhibitor compound
HK1230164B (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221019